Abstract
In neuropathic non infected wounds, growth factors give good results. PDGF and EGF are only two growth factors available in the market. They should be used with proper wound care practices with wound bed preparation, offloading and immobilization. Male and female sex hormones also play a role in healing process.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Jude EB, Blakytny R, Bulmer J, et al. Transforming growth factor-beta 1,2,3 and receptor type I and II in diabetic foot ulcers. Diabet Med. 2002;19:440–7.
Lynch SE, Nixon JC. Role of platelet derived growth factor in wound healing: synergistic effects with growth factors. Proc Natl Acad Sci U S A. 1987;84:7696–7.
Robson M, Phillips L. Platelet derived growth factor BB for the treatment of chronic pressure ulcers. Lancet. 1992;339:23–5.
Mustoe T, Culter N. A phase II study to evaluate recombinant platelet derived growth factor BB in the treatment of stage 3 and 4 pressure ulcers. Arch Syrg. 1994;129:212–9.
Steed DL. Diabetic ulcer Study group: clinical evaluation of recombinant human platelet derived growth factor for the treatment of lower extremity diabetic foot ulcers. J Vasc Surg. 1995;21:71–81.
Steel DL. Clinical evaluation of recombinant human platelet derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic ulcer Study group. J Vasc Surg. 1995;21:71–8.
Weiman TJ, Smiel JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet derived growth factor BB in patients with chronic neuropathic ulcers. A phase 3 randomized placebo controlled double blind study. Diabetes Care. 1998;21:822–37.
Bhansali A, Venkatesh S, Duttta P, et al. Which is the better option: recombinant human PDGF-BB 0.01% gel or standard wound care, in diabetic neuropathic large planter ulcers off loaded by a customized contact cast? Diabetes Res Clin Pract. 2009;83:e 13–6.
Veves A, et al. Chapter 20: Role of growth factors in the treatment of diabetic foot. In: The diabetic foot. 2nd ed. Totowa, NJ: Humana Press; 2006. p. 453–4.
Sporn MB, Robert AB. Transforming growth factor. JAMA. 1989;262:938–41.
Knighton DR, Ciresi KF. Classifications and treatment of chronic non healing wounds. Ann Surg. 1986;104:322–30.
Atri SC, Misra J. Use of homologous platelet factors in achieving total healing of recalcitrant skin ulcers. Surgery. 1990;108:508–12.
Kirsner RS, Michela M, Stasik L, et al. Advanced biological therapies for diabetic foot ulcers. Arch Dermatol. 2010;146(8):857–62.
Kantor J, Margolis DJ. Treatment options for diabetic neuropathic foot ulcers: a cost effectiveness analysis. Dermatol Surg. 2001;27:347–51.
Ashcroft GS, Green-Wild T, Horan MA, Wahl SM, Ferguson MW. Topical estrogen accelerates cutaneous wound healing in aged humans associated with an altered inflammatory response. Am J Pathol. 1999;155:1137–46.
Ashcroft GS, Dodsworth J, van Boxtel E, et al. Estrogen accelerates cutaneous wound healing associated with an increase in TGF-β 1 levels. Nat Med. 1997;3:1209–15.
Taylor RJ, Taylor AD, Smyth JV. Using an artificial neural network to predict healing times and risk factors for venous leg ulcers. J Wound Care. 2002;11:101–5.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Vachhrajani, V., Khakhkhar, P. (2020). Growth Factors (Third Generation Wound Healing Agents) and Hormones. In: Science of Wound Healing and Dressing Materials. Springer, Singapore. https://doi.org/10.1007/978-981-32-9236-9_9
Download citation
DOI: https://doi.org/10.1007/978-981-32-9236-9_9
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-32-9235-2
Online ISBN: 978-981-32-9236-9
eBook Packages: MedicineMedicine (R0)